Summary
Purpose: To describe a phase II study design to evaluate the activity of novel anti-cancer agents that focuses on molecular pathogenesis rather than tumor histology. Methods: We propose an enrichment design that enrolls patients across histologies expressing target X and incorporates randomized discontinuation of drug Y after an initial treatment period to evaluate for potential cystostatic activity. Results: We are currently evaluating the activity of lapatinib in patients with HER-2 amplified solid tumors using the target-specific, histology-independent, randomized discontinuation design. Patients receive treatment with lapatinib for an initial 12-week period. After restaging, patients with disease progression are removed from study, patients achieving an objective response continue treatment, and patients with stable disease are randomized to continue lapatinib versus initiate treatment with placebo. The primary endpoints are to evaluate the objective response rate during the initial treatment period and to evaluate the proportion of patients progression-free 12 weeks post-randomization. Conclusion: The target-specific, histology-independent, randomized discontinuation design is an attractive alternative to the traditional phase II design for the development of “targeted” therapeutics.
References
Millar AW, Lynch KP (2003) Rethinking clinical trials for cytostatic drugs. Nat Rev 3:540–545
Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648
Rosner GL, Stadler W, Ratain MJ (2002) Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20:4478–4484. doi:10.1200/JCO.2002.11.126
Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134. doi:10.1056/NEJMoa060655
Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512. doi:10.1200/JCO.2005.03.6723
Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D (1995) c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett’s oesophagus. J Clin Pathol 48:129–132. doi:10.1136/jcp.48.2.129
Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC (1992) HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47:179–185. doi:10.1016/0090-8258(92)90103-P
Miyamoto H, Kubota Y, Noguchi S et al (2000) C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55:679–683. doi:10.1016/S0090-4295(99)00604-4
Park DI, Yun JW, Park JH et al (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371–1379. doi:10.1007/s10620-005-9057-1
Lara PN Jr, Meyers FJ, Gray CR et al (2002) HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer 94:2584–2589. doi:10.1002/cncr.10526
Baselga J, Rosen N (2008) Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol 26:1582–1584. doi:10.1200/JCO.2007.15.3700
Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF (2007) Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 25:265–270. doi:10.1007/s10637-006-9020-9
Gordon MS, Matei D, Aghajanian C et al (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:4324–4332. doi:10.1200/JCO.2005.05.4221
Kulke MH, Muzikansky A, Clark J et al (2006) A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest 24:346–350. doi:10.1080/07357900600705268
Hussain MH, MacVicar GR, Petrylak DP et al (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25:2218–2224. doi:10.1200/JCO.2006.08.0994
Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634. doi:10.1200/JCO.2007.14.7116
Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024. doi:10.1056/NEJMoa051918
Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G (2005) Prostate cancer clinical trial end points: “RECIST”ing a step backwards. Clin Cancer Res 11:5223–5232. doi:10.1158/1078-0432.CCR-05-0109
Sevinc A, Turhal NS (2008) ‘Please, desist RECIST criteria in GIST, at least in me’. Onkologie 31:556. doi:10.1159/000151688
Acknowledgements
NIH PO1 Grant #5PO1CA109522
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Galsky, M.D., Zaks, T., Hassani, H. et al. Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs 28, 194–198 (2010). https://doi.org/10.1007/s10637-009-9239-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-009-9239-3